Cardiac DiseaseURBACAM-DNCT06957548
Cardiometabolic Disease Risk Factors in Cameroon
An observational study of Cardiac Disease and Metabolic Disease, run by Johns Hopkins University at 1 site in Cameroon.
Trial summary
Cardiometabolic diseases (CMDs) are a major public health concern in sub-Saharan Africa, including Cameroon. Studies have shown a significant increase in the prevalence of hypertension, diabetes, and obesity in recent years. Read more about this study
- Who is it for?
- Ages 18 years and olderHealthy volunteers can take part
- Conditions the study is for
- Cardiac Disease, Metabolic Disease
- What is being tested?
- Cardiometabolic disease
- How many people
- 200 participants
- Where
- 1 siteCameroon
- Study dates
- 9 Jul 2025to 12 Feb 2027
- Phase
- Observational
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 years and older
- All sexes
- Healthy volunteers accepted
- Adult, Older adult
Study population: Urban Cameroon. Newbell, Douala, cameroon.
Who may be able to join
- Screening is open to any adult over the age of 18 years
Who cannot join
None listed.
Trial locations and contacts
1 site in 1 country. Contact the study team or a site near you to ask about taking part.
About this study
Official title: Screening for Cardiometabolic Disease Risk Factors: a Community Health Screening Program in Urban Cameroon
Cardiometabolic diseases (CMDs) are a major public health concern in sub-Saharan Africa, including Cameroon. Studies have shown a significant increase in the prevalence of hypertension, diabetes, and obesity in recent years. However, access to timely diagnosis and treatment remains limited, particularly in rural areas. Community-based screening programs have been shown to be effective in identifying individuals with undiagnosed CMD risk factors and promoting early intervention. By leveraging the strengths of community-based approaches, the URBACAM-D study aims to address the growing burden of CMDs in urban Cameroon.
- Conditions
- Cardiac Disease, Metabolic Disease
- Being tested
- Cardiometabolic disease
- Medical subject headings
- Heart Diseases, Metabolic Diseases
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Cardiometabolic diseaseDiagnostic test
Cardiometabolic disease screening
What is being measured
The primary outcome is the main question the study is designed to answer.
Prevalence of Cardiometabolic disease risk factors in Urban Cameroon
To determine the prevalence of undiagnosed and uncontrolled cardiometabolic disease (CMD) risk factors among urban Cameroonians.
Measured: 1 year
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted4 May 2025
- Study start9 Jul 2025
- Primary completion12 Oct 2025
- Study completion12 Feb 2027 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Cardiac DiseaseStudies of the same condition, open and under way.
- More trials run by Johns Hopkins UniversityThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Other
- Time perspective
- Cross-sectional
- Enrolment
- 200 participants (estimated)
Sponsor and investigators
- Lead sponsor
- Johns Hopkins University
- Sponsor type
- University, hospital or other
- Responsible party
- Sponsor
- Investigators
- Dimitri Tito, DO, Principal investigator, Johns Hopkins University
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT06957548
- Sponsor's protocol ID
- IRB00474444
- Acronym
- URBACAM-D
- Status last verified
- Nov 2025
- First submitted
- 25 Apr 2025
- Last updated
- 26 Nov 2025
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No